



**Figure S2. Primary tumor incidence and growth in *Braf<sup>CA</sup>;Cdkn2a<sup>fl/fl</sup>* mice is not altered by ARF6-GTP.** (a) Primary tumor incidence (% = # of mice that developed a tumor / # TVA positive, injected mice) in control and overlapping *Arf6<sup>Q67L</sup>* cohorts. Two *Arf6<sup>Q67L</sup>* cohorts, classified according to detectable or undetectable HA-tagged *Arf6<sup>Q67L</sup>* expression by qRT-PCR and/or by anti-HA immunohistochemistry (see Figure S1). Cohort A includes all mice injected with RCAS Cre + *Arf6<sup>Q67L</sup>*. Cohort B is limited to only those mice from cohort A with detectable *Arf6<sup>Q67L</sup>* in tumors. Fisher's exact test, two tailed,  $\alpha < 0.05$ . (b) Primary tumor growth upon tumor onset, bars = SD. (c) Overall survival upon tumor onset, log-rank (Mantel-Cox) test. (d) Metastatic incidence (# mice with metastasis / # mice with primary tumors). (e) Proliferation, *Braf<sup>CA</sup>;Cdkn2a<sup>fl/fl</sup>* mouse melanoma cells. (f) Apoptosis, *Braf<sup>CA</sup>;Cdkn2a<sup>fl/fl</sup>* mouse melanoma cells. (g) Representative images of Ki67 immunostains, 200x magnification, scale bars = 50 $\mu$ m.